Patent challenger Natco is now Gilead licensee for Sovaldi

Patent challenger Natco Pharma has made a strategic about turn and has now emerged as a licensee for Gilead Sciences's blockbuster hepatitis C therapy, Sovaldi (sofosbuvir).

Patent challenger Natco Pharma has made a strategic about turn and has now emerged as a licensee for Gilead Sciences's blockbuster hepatitis C therapy, Sovaldi (sofosbuvir).

Natco informed Indian bourses that it had signed a non-exclusive licensing pact with Gilead, to manufacture and sell generic versions...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia